{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T11:03:46Z","timestamp":1785323026277,"version":"3.55.0"},"reference-count":14,"publisher":"Baskent University","issue":"Supp 2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Clin Transplant"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.6002\/ect.mesot2025.p50","type":"journal-issue","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T11:39:50Z","timestamp":1785238790000},"source":"Crossref","is-referenced-by-count":0,"title":[],"prefix":"10.6002","volume":"24","member":"4021","reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1. Cheung CY, Man Ma MK, Chak WL, Chau KF, Tang SC. Conversion to mammalian target of rapamycin inhibitors in kidney transplant recipients with de novo cancers. Oncotarget. 2017;8(27):44833-44841. doi:10.18632\/oncotarget.14908","DOI":"10.18632\/oncotarget.14908"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2. Cangemi M, Montico B, Fa\u00e8 DA, Steffan A, Dolcetti R. Dissecting the multiplicity of immune effects of immunosuppressive drugs to better predict the risk of de novo malignancies in solid organ transplant patients. Front Oncol. 2019;9:160. doi:10.3389\/fonc.2019.00160","DOI":"10.3389\/fonc.2019.00160"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. Rodr\u00edguez-Per\u00e1lvarez M, Crespo G, Rivera J, et al. Cumulative exposure to tacrolimus and incidence of cancer after liver transplantation. Am J Transplant. 2022;22(6):1671-1682. doi:10.1111\/ajt.17021","DOI":"10.1111\/ajt.17021"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. Balan M, Chakraborty S, Pal S. Signaling Molecules in posttransplantation cancer. Clin Lab Med. 2019;39(1):171-183. doi:10.1016\/j.cll.2018.10.006","DOI":"10.1016\/j.cll.2018.10.006"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5. Fenoglio R, Roccatello D, Simone ED, et al. The challenging management of cancer: an immunonephrologist's perspective. Kidney Blood Press Res. 2021;46(1):114-120. doi:10.1159\/000511256","DOI":"10.1159\/000511256"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6. Lim LM, Kung LF, Kuo MC, Huang AM, Kuo HT. Timing of mTORI usage and outcomes in kidney transplant recipients. Int J Med Sci. 2021;18(5):1179-1184. doi:10.7150\/ijms.53655","DOI":"10.7150\/ijms.53655"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7. Maenosono R, Okumi M, Unagami K, et al. Urothelial carcinoma associated with BK polyomavirus infection after kidney transplantation. Ren Replace Ther. 2020;6:52. doi:10.1186\/s41100-020-00297-6","DOI":"10.1186\/s41100-020-00297-6"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8. Ma\u0142yszko J, Bamias A, Danesh FR, et al; Conference Participants. KDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantation. Kidney Int. 2020;98(6):1407-1418. doi:10.1016\/j.kint.2020.07.012","DOI":"10.1016\/j.kint.2020.07.012"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9. Cheung CY, Man Ma MK, Chak WL, Chau KF, Tang SC. Conversion to mammalian target of rapamycin inhibitors in kidney transplant recipients with de novo cancers. Oncotarget. 2017;8(27):44833-44841. doi:10.18632\/oncotarget.14908","DOI":"10.18632\/oncotarget.14908"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10. Zimak Z, Mokos I, Sai\u0107 H, et al. Management of prostate cancer in kidney transplant recipients. Acta Clin Croat. 2023;62(Suppl 2):110-113. doi:10.20471\/acc.2023.62.s2.15","DOI":"10.20471\/acc.2023.62.s2.15"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11. Velvet AJJ, Bhutani S, Papachristos S, et al. A single-center experience of post-transplant lymphomas involving the central nervous system with a review of current literature. Oncotarget. 2019;10(4):437-448. doi:10.18632\/oncotarget.26522","DOI":"10.18632\/oncotarget.26522"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12. White ML, Moore DW, Zhang Y, Mark KD, Greiner TC, Bierman PJ. Primary central nervous system post-transplant lymphoproliferative disorders: the spectrum of imaging appearances and differential. Insights Imaging. 2019;10(1):46. doi:10.1186\/s13244-019-0726-6","DOI":"10.1186\/s13244-019-0726-6"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13. Kami\u0144ska D, Krajewska M, Mazanowska O, Pozna\u0144ski P, Boraty\u0144ska M, Klinger M. Post-transplant lymphoproliferative disorder in adult renal transplant recipients: case series and review of literature. Cent Eur J Immunol. 2020;45(4):498-506. doi:10.5114\/ceji.2020.103427","DOI":"10.5114\/ceji.2020.103427"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14. Gottlieb J, Fischer B, Schupp JC, Golpon H. Calcineurin-inhibitor free immunosuppression after lung transplantation - a single center case-control study in 51 patients converted to mechanistic target of rapamycin (mTOR) inhibitors. PLoS One. 2023;18(5):e0284653. doi:10.1371\/journal.pone.0284653","DOI":"10.1371\/journal.pone.0284653"}],"container-title":["Experimental and Clinical Transplantation"],"original-title":[],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T10:31:48Z","timestamp":1785321108000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ectrx.org\/detail\/supplement\/2026\/24\/6\/2\/413\/0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":14,"journal-issue":{"issue":"Supp 2","published-print":{"date-parts":[[2026,7]]}},"URL":"https:\/\/doi.org\/10.6002\/ect.mesot2025.p50","relation":{},"ISSN":["1304-0855","2146-8427"],"issn-type":[{"value":"1304-0855","type":"print"},{"value":"2146-8427","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}